Jay Champaneri recently joined CryoXtract as Manager of European Sales. He is an accomplished professional with a significant track record of success within laboratory instrumentation in drug discovery and bioscience research. He brings particular expertise in the areas of cell biology, proteomics, genomics, imaging, and HTS/HCS.
Topics: Executive Spotlight
There is a strong belief among scientists that understanding microbial communities will lead to advances in environmental protection and human health. In recent articles published in Science and Nature and summarized by The New York Times here, researchers called for government support of a national microbiome initiative to study microbial communities. Such an initiative could lead to better understanding of the role of the microbiome in disease progression and prevention, as well as offer further opportunities to investigate the potential of microbiome manipulations such as fecal transplantations.
In a recent article in Hutch News, found here, the gut microbiome was shown to have a negative effect on the success of HIV vaccines. The recent HIV vaccine tested boosted production of antibodies that bind both the HIV virus and several intestinal bacteria. Researchers suspect that the HIV virus mimics common gut microbia that are not targeted by the immune system. Future vaccine trials will involve infants with undeveloped immune systems, hoping to circumvent the protective effects of the gut microbiome. In addition, future vaccine trials will incorporate gut microbiome analysis to further understand the link between vaccine effectiveness and the microbiome.
CryoXtract is excited to participate in this year's Global Engage Microbiome R&D and Business Collaboration Forum in San Diego. The event on September 10th and 11th brings together over 200 industry leaders for engaging panel discussions, presentations and exhibition. Key topics include highlights of new microbiome research, discussions of venture and other capital investment in the field, and more.
A July, 2015 publication of a study in Scientific Reports found here investigates the interactions between gut microbiota and berberine, a dietary supplement used for the treatment of lipid- and glucose-related disorders. In the study, researchers found that gut microbiota reduced berberine to an absorbable form in the intestine, increasing its effectiveness. The authors conclude that there can be critical interaction between intestinal bacteria and orally-administered drugs and suggest that the effect of gut microbiota on orally-administered drug metabolism should be investigated during drug development.
A recent article in Genetic Engineering and Biotech News, found here, discusses the necessity of and options for improved biospecimen tracking, procurement, and distribution that extends beyond biobanks alone. The authors emphasize the importance of rich analytical biospecimen data, dynamic sample collection, and efficient sample distribution. With the ultimate goal to propel biobanking forward in order to efficiently support the advancement of personalized medicine, frozen aliquotting technology’s ability to preserve biospecimen integrity and increase utilization is key to this goal.
Failures in incurred sample reanalysis (ISR) can be very problematic to life science researchers working in drug discovery and regulated bioanalysis. As a tool for confirming reliability of bioanalytical measurements, concerns with and failures of ISR can significantly delay drug development and can be very costly to remedy. An article in AAPS earlier this year (found here) discusses difficulties with ISR imprecision particularly in small molecule studies.
Integrating data from tissue imaging, genomic databases, and clinical results could be a major key in the journey toward truly personalized medicine, according to a recent article in Genetic Engineering and Biotechnology News (found here). Careful maintenance of patient data correlated with tissue samples is one element of the best practices necessary for a truly integrated data approach to drug discovery and development.